Dosimetric evaluation of iodine-125 brachytherapy for brain tumors using MR guidance combined with a three-dimensional non co-planar template

Published:January 09, 2023DOI:



      To investigate the consistency between preoperative and postoperative dosimetry when 125I brachytherapy for brain tumors is performed with magnetic resonance (MR) guidance and a three-dimensional non co-planar template (3DNPT).


      Thirty patients with brain tumors (metastatic or gliomas) underwent radioactive 125I seed implantation. A preoperative treatment plan was determined with MR imaging, and the operation was done under 3DNPT assistance and MR guidance. The dosimetry was verified postoperatively based on postoperative CT–MR fusion images. Postoperative dosimetric parameters and implant quality indices were defined and compared with those in the preoperative treatment plan. Furthermore, a comparison of preoperative and postoperative doses to normal brain tissues and organs at risk was also performed.


      All mean postoperative dosimetries were calculated. Target coverage parameters D90, D100, %CTV100, %CTV150, and %CTV200 were 143.6 cGy, 76.6 cGy, 88.2%, 63.1%, and 41.4%, respectively. The values of implant quality indices CI, EI, and HI were 0.75, 0.14, and 0.28, respectively. No significant differences between most preoperative and postoperative dosimetric parameters were found (p > 0.05). The differences were also insignificant for organs at risk. Postoperative %CTV150 and %CTV200 were higher than the preoperative, whereas postoperative HI was significantly lower than in the treatment plan.


      Magnetic resonance guidance combined with 3DNPT allows accurate positioning and direction in 125I brachytherapy for brain tumors. However, seed distribution and dose homogeneity require further improvement.



      CI (coverage index), D (dose), EI (external volume index), HI (relative dose homogeneity index), V (target or tumor volume)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ostrom QT
        • Gittleman H
        • Fulop J
        • et al.
        CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012.
        Neuro Oncol. 2015; 17: iv1-iv62
        • Diamandis P
        • Aldape K.
        World Health Organization 2016 classification of central nervous system tumors.
        Neurol Clin. 2018; 36: 439-447
        • Michael W
        • Martin van den B
        • Matthias P
        • et al.
        EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.
        Nat Rev Clin Oncol. 2021; 18: 170-186
        • Christoph S
        • Alexander R
        • Niklas T
        • et al.
        Outcome and toxicity profile of salvage low-dose-rate iodine-125 stereotactic brachytherapy in recurrent high-grade gliomas.
        Acta Neurochir. 2015; 157: 1757-1764
        • Huang K
        • Sneed PK
        • Kunwar S
        • et al.
        Surgical resection and permanent iodine-125 brachytherapy for brain metastases.
        J Neuro-Oncol. 2009; 91: 83-93
        • Julie DA
        • Lazow SP
        • Vanderbilt DB
        • et al.
        A matched-pair analysis of clinical outcomes after intracavitary cesium-131 brachytherapy versus stereotactic radiosurgery for resected brain metastases.
        J Neurosurg. 2020; 134: 1447-1454
        • Silke BS
        • Niklas T
        • Katharina N
        • et al.
        Iodine-125 brachytherapy for brain tumours – a review.
        Radiat Oncol. 2012; 7: 30-58
        • Ferreira C
        • Sterling D
        • Reynolds M
        • et al.
        First clinical implementation of GammaTile permanent brain implants after FDA clearance.
        Brachytherapy. 2021; 20: 673-685
        • Wang C
        • Liu C
        • Chen J
        • et al.
        Effect of neoadjuvant iodine-125 brachytherapy upon resection of glioma.
        BMC Cancer. 2022; 22: 397-408
        • Metcalfe P
        • Liney GP
        • Holloway L
        • et al.
        The potential for an enhanced role for MRI in radiation-therapy treatment planning.
        Technol Cancer Res Treat. 2013; 12: 429-446
      1. Chinese National Health and Family Planning Commission. Requirements for radiological protection of seed sources in permanent implanted treatment. GBZ178-2017.

        • Igor D
        • Borislava P
        • Marko E
        • et al.
        Radiotherapy treatment planning: benefits of CT-MR image registration and fusion in tumor volume delineation.
        Vojnosanit Pregl. 2013; 70: 735-739
        • He X
        • Liu M
        • Liu C
        • et al.
        A novel three-dimensional template combined with MR-guided I-125 brachytherapy for recurrent glioblastoma.
        Radiat Oncol. 2020; 15: 146-156
        • Rivard MJ
        • Coursey BM
        • DeWerd LA
        • et al.
        Update of AAPM task group No. 43 report: a revised AAPM protocol for brachytherapy dose calculations.
        Med Phys. 2004; 31: 633-674
        • Hodapp N.
        The ICRU Report No. 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT).
        Strahlenther Onkol. 2012; 188: 97-99
        • Meertens H
        • Borger J
        • Steggerda M
        • et al.
        Evaluation and optimization of interstitial brachytherapy dose distributions.
        in: Mould RF Battermann JJ Martinez AA Speiser BL Brachytherapy from radium to optimization. Nucletron International, Veenendaal, The Netherlands1994: 300-306
        • Dimos B
        • Christos K
        • Konstantina G
        • et al.
        A conformal index (COIN) to evaluate implant quality and dose specification in brachytherapy.
        Int J Radiat Oncol Biol Phys. 1998; 40: 515-524
        • Lawrence BM
        • Ellen DY
        • Andrew J
        • et al.
        Use of normal tissue complication probability models in the clinic.
        Int J Radiat Oncol Biol Phys. 2010; 76: s10-s19
        • Nachbichler SB
        • Kreth FW.
        Brachytherapy of intracranial gliomas.
        Prog Neurol Surg. 2018; 31: 72-86
        • Wang C
        • Liu S
        • Peng L
        • et al.
        Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas.
        BMC Cancer. 2020; 24: 591-599
        • Liu S
        • Wang H
        • Wang C
        • et al.
        Dosimetry verification of 3D-printed individual template based on CT-MRI fusion for radioactive 125I seed implantation in recurrent high-grade gliomas.
        Contemp Brachyther. 2019; 11: 235-242
        • Kaal EC
        • Vecht CJ.
        The management of brain edema in brain tumors.
        Curr Opin Oncol. 2004; 16: 593-600
        • Julow J
        • Kolumbán Z
        • Viola A
        • et al.
        Prediction of volumetric change in the "triple ring" caused by glioma I-125 brachytherapy.
        Neuro Oncol. 2008; 10: 583-592
        • Brahimaj B
        • Lamba M
        • Breneman JC
        • et al.
        Iodine-125 seed migration within brain parenchyma after brachytherapy for brain metastasis: case report.
        J Neurosurg. 2016; 125: 1167-1170
        • Pinnaduwage DS
        • Srivastava SP
        • Yan X
        • et al.
        Dosimetric impacts of source migration, radioisotope type, and decay with permanent implantable collagen tile brachytherapy for brain tumors.
        Technol Cancer Res Treat. 2022; 21: 1-14
        • Akyer SP
        • Cagirici S
        • Ozdemir MB.
        Relationship of age with the size of the interventricular foramina and aqueductus sylvii: a morphometric evaluation.
        Neurol Res. 2014; 36: 878-881
        • Chen WC
        • Katcher J
        • Nunez C
        • et al.
        Radioactive seed migration after transperineal interstitial prostate brachytherapy and associated development of small-cell lung cancer.
        Brachytherapy. 2012; 11: 354-358
        • Hirschfeld CB
        • Schwartz TH
        • Parashar B
        • et al.
        Seed migration to the spinal canal after postresection brachytherapy to treat a large brain metastasis.
        Brachytherapy. 2016; 15: 637-641
        • Warrell GR
        • Xing Y
        • Podder TK
        • et al.
        Reduction of seed motion using a bio-absorbable polymer coating during permanent prostate brachytherapy using a mick applicator technique.
        J Appl Clin Med Phys. 2018; 19: 44-51
        • Benedict SH
        • Yenice KM
        • Followill D
        • et al.
        Stereotactic body radiation therapy: the report of AAPM Task Group 101.
        Med Phys. 2010; 37: 4078-4101
        • Robert CK
        • Sascha D
        • Frank WH
        • et al.
        Image fusion of CT and MRI data enables improved target volume definition in 3D-brachytherapy treatment planning.
        Brachytherapy. 2003; 2: 164-171
        • Jacqueline EZ
        • Jose GR
        • Samantha H
        • et al.
        MRI-based treatment planning and dose delivery verification for intraocular melanoma brachytherapy.
        Brachytherapy. 2017; 17: 31-39
        • Jiang Y
        • Ji Z
        • Guo FX
        • et al.
        Side effects of CT-guided implantation of 125I seeds for recurrent malignant tumors of the head and neck assisted by 3D printing non co-planar template.
        Radiat Oncol. 2018; 13: 18-25
        • Huang MW
        • Zhang JG
        • Zheng L
        • et al.
        Accuracy evaluation of a 3D-printed individual template for needle guidance in head and neck brachytherapy.
        J Radiat Res. 2016; 57: 662-667
        • Ma X
        • Yang PZ
        • Jiang PS
        • et al.
        Effectiveness and safety of a robot-assisted 3D personalized template in 125I seed brachytherapy of thoracoabdominal tumors.
        J Contemp Brachyther. 2018; 10: 368-379
        • Julie DA
        • Lazow SP
        • Vanderbilt DB
        • et al.
        A matched-pair analysis of clinical outcomes after intracavitary cesium-131 brachytherapy versus stereotactic radiosurgery for resected brain metastases.
        J Neurosurg. 2020; 15: 1-8
        • Greenwald J
        • Taube S
        • Yondorf MZ
        • et al.
        Placement of Cs permanent brachytherapy seeds in a large combined cavity of two resected brain metastases in one setting: case report and technical note.
        J Contemp Brachyther. 2019; 11: 356-360
        • Wernicke AG
        • Yondorf MZ
        • Peng L
        • et al.
        Phase I/II study of resection and intraoperative cesium-131 radioisotope brachytherapy in patients with newly diagnosed brain metastases.
        J Neurosurg. 2014; 121: 338-348